A randomised parallel group study to compare transarterial particle embolism with percutaneous ethanol injection in patients with unifocal, small (<3cm), non-resectable hepatocellular carcinoma
| ISRCTN | ISRCTN54481540 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN54481540 |
| Protocol serial number | N0256159469 |
| Sponsor | Department of Health |
| Funders | The Royal Free Hampstead NHS Trust (UK), NHS R&D Support Funding |
- Submission date
- 30/09/2005
- Registration date
- 30/09/2005
- Last edited
- 26/10/2015
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Cancer
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year
Plain English summary of protocol
Not provided at time of registration
Contact information
Prof Andrew K Burroughs
Scientific
Scientific
Department of Liver Medicine & Transplantation
Royal Free Hampstead NHS Trust
Pond Street
Hampstead
London
NW3 2QG
United Kingdom
Study information
| Primary study design | Interventional |
|---|---|
| Study design | Randomised parallel-group study |
| Secondary study design | Randomised controlled trial |
| Study type | Participant information sheet |
| Scientific title | A randomised parallel group study to compare transarterial particle embolism with percutaneous ethanol injection in patients with unifocal, small (<3cm), non-resectable hepatocellular carcinoma |
| Study objectives | Which is the best treatment in terms of survival of patients diagnosed with unresectable unifocal hepatocellular carcinoma (HCC) less than 3 cm in diameter treated with percutaneous ethanol injection or transarterial particle embolisation? |
| Ethics approval(s) | Not provided at time of registration |
| Health condition(s) or problem(s) studied | Cancer: Liver |
| Intervention | Percutaneous ethanol injection or transarterial particle embolisation |
| Intervention type | Drug |
| Phase | Not Applicable |
| Drug / device / biological / vaccine name(s) | Ethanol |
| Primary outcome measure(s) |
Survival of patient after treatment of unresectable, unifocal, small (3 cm) hepatocellular carcinoma |
| Key secondary outcome measure(s) |
Not provided at time of registration |
| Completion date | 31/07/2006 |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Not Specified |
| Sex | Not Specified |
| Target sample size at registration | 185 |
| Key inclusion criteria | Not provided at time of registration |
| Key exclusion criteria | Not provided at time of registration |
| Date of first enrolment | 31/07/2003 |
| Date of final enrolment | 31/07/2006 |
Locations
Countries of recruitment
- United Kingdom
- England
Study participating centre
Royal Free Hampstead NHS Trust
London
NW3 2QG
United Kingdom
NW3 2QG
United Kingdom
Results and Publications
| Individual participant data (IPD) Intention to share | No |
|---|---|
| IPD sharing plan summary | Not provided at time of registration |
| IPD sharing plan |
Study outputs
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| Participant information sheet | Participant information sheet | 11/11/2025 | 11/11/2025 | No | Yes |
